The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2024

Filed:

Apr. 28, 2017
Applicants:

Biomunex Pharmaceuticals, Paris, FR;

Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;

Universite DE Montpellier, Montpellier, FR;

Institut Regional Du Cancer DE Montpellier (Icm), Montpellier, FR;

Inventors:

Eugene Zhukovsky, Paris, FR;

Olivier Leger, Saint Sixt, FR;

Pierre-Emmanuel Gerard, Paris, FR;

Andre Pelegrin, Paris, FR;

Christel Larbouret, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/46 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61P 35/00 (2018.01); C07K 16/468 (2013.01); A61K 38/00 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/53 (2013.01); C07K 2317/73 (2013.01);
Abstract

The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on which two VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) and the light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively.


Find Patent Forward Citations

Loading…